OncoTargets and Therapy是一本国际性的，经过同行评审的期刊，侧重于癌症研究的分子方面，即针对所有类型癌症的分子诊断和靶向分子或精密疗法。 该期刊的特点是对高质量原创研究，基础科学，评论和评估，专家意见和评论的快速报道，从而为癌症或癌症亚型提供了新颖的见解。 该期刊涵盖的具体主题包括： 新型治疗靶标和创新药物 改善疗效和/或减少副作用的新型治疗方案 早期临床试验 提交OncoTargets和Therapy时的其他注意事项： 包含体内动物模型数据的研究将被认为是有利的。 除非在涉及多个细胞系的全面生物学研究的支持下，否则将不考虑组织微阵列分析。 仅当通过全面的体外数据和人体组织样品分析进行验证时，才会考虑生物标志物关联研究。 利用公开可用数据（例如GWAS / TCGA / GEO等）进行的研究应增加关于特定疾病或相关表型的知识，并且必须通过在独立样本集中进行复制并使用以下功能使用作者自己的数据进行验证：起来。 生物信息学研究必须使用作者自己的数据通过在独立样本集中的复制和功能随访进行验证。 将不考虑单核苷酸多态性（SNP）研究。 如果将重点放在分子病理学上，则将考虑病例报告和方案，并为文献做出有价值的原创贡献。 自2019年3月18日起，OncoTargets和Therapy将不再考虑进行荟萃分析以发表。


OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: Novel therapeutic targets and innovative agents Novel therapeutic regimens for improved benefit and/or decreased side effects Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: Studies containing in vivo animal model data will be considered favorably. Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. Single nucleotide polymorphism (SNP) studies will not be considered. Case reports and protocols will be considered if focused on molecular pathology and make a valuable and original contribution to the literature. As of 18th March 2019, OncoTargets and Therapy will no longer consider meta-analyses for publication.